BioSpace News Archive

Amneal Pharmaceuticals, Inc. announced its results for the fourth quarter and full year ended December 31, 2020.

Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo ® (nivolumab) in Combination with Cabometyx ® (cabozantinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma

Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the European Medicines Agency (EMA) has validated for review the Marketing Authorization Application (MAA) for somatrogon, a long-acting recombinant human growth hormone that is intended to be administered once-weekly for the treatment of pediatric patients with growth hormone deficiency (GHD)

Exelixis, Inc. (NASDAQ: EXEL) today announced that its partner Ipsen received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), for CABOMETYX® (cabozantinib) in combination with OPDIVO® (nivolumab)

Fact.MR, a global research & consulting firm, in their latest edition of the report, projected that the renovascular hypertension treatment market is anticipated to see moderate growth pace in 2021 and beyond.

Fact.MR, a global research & consulting firm, in their updated edition of the report, indicated that the renal artery stenosis treatment market is projected to foresee a moderate growth in 2021 and beyond.